At present, the novel coronavirus pneumonia situation in China has gradually improved, and vaccination has been over 2 billion 100 million doses. Many people are concerned about the progress of researchers in the research and development of effective clinical drugs.
A few days ago, CCTV interview with Zhang Yuntao, chief scientist of Chinese medicine, China Pharmaceutical Group, said that the current global vaccine research and development has entered the hottest stage. Nearly 300 vaccines in the world have been involved in clinical research in 100 cases, and more than 20 have entered the three phase clinical research. The vaccine has played a very important role in COVID-19's global prevention and control.
But at the same time, the needleResearch and development of effective drugs for COVID-19 is also very important. Scientists all over the world are working hard to develop a series of drugs to prevent the infection of new crown.
For now,The drugs developed by various teams and institutions have successively entered the preclinical and clinical phase I and phase II research stages. It is estimated that effective drugs may be developed in the next two or three years.
According to the official news of Sinopharm group, the new crown specific drug launched by Sinopharm group attracted much attention at the 2021 Service Trade Fair held recently., On August 30, the intravenous covid-19 human immunoglobulin (pH4) developed by Sinopharm China biology obtained the approval for drug clinical trial issued by the State Drug Administration and was approved to carry out clinical trial.
According to the introduction, intravenous injection of COVID-19 Human Immunoglobulin (pH4) is a specially designed Human Immunoglobulin with high efficiency SARS-CoV-2 neutralizing antibody prepared from the healthy human plasma after the approval of the China's biological New Coronavirus inactivated vaccine, and purified by low-temperature ethanol protein purification method.
- THE END -
Please indicate the source of Reprint: fast technology